Australia Approves First Type 1 Diabetes Delay Drug

For the first time since insulin was discovered over a century ago, doctors can now delay type 1 diabetes before symptoms even appear.

Australia's Therapeutic Goods Administration has approved Tzield, a therapy that targets the immune attack causing type 1 diabetes in its early stages. The drug can delay progression to clinical diagnosis by an average of two years, giving people aged eight and older valuable time without insulin injections and constant glucose monitoring.

The approval represents nearly four decades of research funded by Breakthrough T1D, the leading nonprofit organization dedicated to type 1 diabetes. They've invested in the therapy since 1988, supporting pioneering scientists through early discovery research all the way to landmark clinical trials.

Tzield works differently than anything before it. Instead of treating diabetes after diagnosis, it intervenes during stage 2, when blood glucose changes have started but insulin isn't yet needed. By targeting the underlying immune response, the therapy slows the disease's march toward full clinical onset.

Nineteen-year-old Jess Kovacs knows this gift of time personally. After her younger sister was diagnosed with type 1 diabetes at age seven, Jess was screened and discovered she had early stage disease. She received Tzield treatment earlier this year.

"It has given me so much hope that I still have a life to live without T1D for a while," Jess said. "It's given me back some control, which is so empowering in the face of this condition."

The Ripple Effect

The approval's impact extends far beyond individual patients. An estimated 25,000 Australians are unknowingly living with early stage type 1 diabetes right now, and screening is the only way to find them before symptoms develop.

Australia has become a global leader in type 1 diabetes screening thanks to nearly $10 million invested by Breakthrough T1D to build detection infrastructure nationwide. This combination of screening programs and breakthrough therapies creates a completely new approach to managing the condition.

For the 145,000 Australians currently living with type 1 diabetes, the approval offers something even more powerful than medical progress. It offers hope that future generations might have a fundamentally different experience with the disease.

The next step is listing Tzield on the Pharmaceutical Benefits Scheme to make it widely accessible. Breakthrough T1D Australia Chief Executive Sydney Yovic emphasized that every day without the relentless burden of diabetes management matters deeply to families, reducing both the daily challenges and long-term health complications.

After 100 years of only one option, families facing type 1 diabetes finally have a second choice.